Who
Lawrence A. Kenyon
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Outlook Therapeutics; Chief Financial Officer, Arno Therapeutics; President, CEO and CFO, Tamir Biotechnology; EVP, Chief Financial Officer, Par Pharmaceutical Companies; CFO and Secretary, Neopharm.
In numbers
- Trades disclosed
- 58
- Buys
- 5
- Sells
- 5
- Bought
- $123K
- Sold
- $583K
- Companies
- 5
- Companies where not an officer
- 0
- First trade
- 25 Jan 2006
- Last trade
- 14 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Aug 2026filed 14 Aug 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | —101,010 | filing |
| 14 Aug 2026filed 14 Aug 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —101,010 | filing |
| 14 Aug 2026filed 14 Aug 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —101,010 | filing |
| 14 Aug 2026filed 14 Aug 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | —101,010 | filing |
| 21 Jul 2026filed 23 Jul 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —210,078 at $0.00 | filing |
| 21 Jul 2026filed 23 Jul 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —210,078 at $0.00 | filing |
| 26 Sep 2024filed 30 Sep 2024 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $28K5,000 at $5.69 | filing |
| 20 Mar 2024filed 22 Mar 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 20 Apr 2021filed 20 Apr 2021 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $18K10,000 at $1.83 | filing |
| 1 Oct 2020filed 5 Oct 2020 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,668,984 at $0.00 | filing |
| 17 Jul 2020filed 21 Jul 2020 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 19 Mar 2020filed 20 Mar 2020 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —216,435 at $0.00 | filing |
| 18 Sep 2019filed 15 Oct 2019 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,2951,350 at $1.70 | filing |
| 18 Sep 2019filed 23 Sep 2019 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,2951,350 at $1.70 | filing |
| 12 Sep 2019filed 13 Sep 2019 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 19 Feb 2019filed 19 Feb 2019 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 7 Feb 2019filed 8 Feb 2019 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $23K25,000 at $0.90 | filing |
| 18 Sep 2018filed 18 Sep 2018 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Sold | $8,78710,100 at $0.87 | filing |
| 1 Aug 2018filed 3 Aug 2018 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 22 Dec 2017filed 26 Dec 2017 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Sold | $30K26,165 at $1.13 | filing |
News
Reviewing Aprea Therapeutics (NASDAQ:APRE) & Oncobiologics (NASDAQ:OTLK)OTLK · themarketsdaily.com · 20 Oct 2026
0 headlines in the last 90 days name Lawrence A. Kenyon; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.